Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Lehman on Breast MRI and Mastectomy

September 13th 2013

Constance D. Lehman, MD, PhD, from the Seattle Cancer Care Alliance, discusses how imaging can guide a women with breast cancer to make treatment decisions.

Dr. Steensma on ODAC's Pertuzumab Decision

September 12th 2013

David P. Steensma, MD, from the Dana-Farber Cancer Institute, provides insight into the ODAC decision to recommend approval for a neoadjuvant pertuzumab-containing regimen for patients with HER2-positive breast cancer.

In Historic Vote, ODAC Suggests Approval of Neoadjuvant Pertuzumab Regimen

September 12th 2013

The FDA's Oncologic Drugs Advisory Committee voted 13-0 with one abstention in support of pertuzumab in combination with trastuzumab and docetaxel for patients with HER2-positive breast cancer in the neoadjuvant setting.

Suzanne Fuqua on the Interaction Between ER and AR

September 12th 2013

Suzanne A. W. Fuqua, PhD, professor of medicine, Baylor College of Medicine, talks about the interaction between estrogen receptors (ER) and androgen receptors (AR) in patients with breast cancer.

Breakthrough Designation Granted to Entinostat for Advanced Breast Cancer

September 11th 2013

The novel HDAC inhibitor entinostat in combination with exemestane has received a Breakthrough Therapy designation from the FDA for its potential to reverse resistance to hormonal therapies used to treat patients with advanced ER-positive breast cancer.

FDA Panel Set to Vote on Milestone Neoadjuvant Pertuzumab Combo

September 11th 2013

The hope for many targeted therapies is that they will eventually be used in patients with earlier stage disease; for the breast cancer drug pertuzumab (Perjeta), that hope is being put to the test.

Dr. Garcia on the Future Role of PARP inhibitors

September 9th 2013

Agustin A. Garcia, MD, associate professor of medicine, Keck School of Medicine of the University of Southern California, discusses the future role of PARP inhibitors for patients with ovarian cancer and breast cancer.

Rugo Offers Window Into Evolving Views of ER-Positive Disease

September 6th 2013

Research efforts are under way to improve the efficacy of hormone therapy in the management of advanced estrogen receptor-positive (ER) breast cancer, including new strategies for targeting the PI3K/ mTOR pathway.

Dr. Finn on the Phase III Trial of Palbociclib for Breast Cancer

September 6th 2013

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes the design of a phase III trial looking at palbociclib for the treatment of patients with estrogen receptor-positive metastatic breast cancer.

Puma Begins Phase III Development of Neratinib in Breast Cancer

September 6th 2013

Puma Biotechnology is a Los Angeles-based development stage biopharmaceutical company that has spent the last couple of years focused on the development of its lead drug candidate, neratinib (PB272).

Analyzing the Nuances of Trastuzumab Therapy for HER2-Positive Breast Cancer

September 3rd 2013

Trastuzumab is the clear standard of care for firstline therapy for nearly all HER2-positive breast cancers, and the oncology community has come a long way toward understanding how best to use the drug.

Dr. Mittendorf on Cyclin E as a Target in Breast Cancer

August 29th 2013

Elizabeth Mittendorf, MD, PhD, Assistant Professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, discusses the potential to target cyclin E in breast cancer.

Did Our Founding Fathers Get It Right?

August 28th 2013

Only Time Will Tell the Far-Reaching Societal Implications of the Supreme Court's BRCA 1/2 Ruling

TNBC Studies Yield Clues for Future Directions

August 27th 2013

Researchers are still at the drawing board when it comes to finding revolutionary solutions for the treatment of triple-negative breast cancer, but studies have shed light on the diversity of the disease and offered hints about the directions future inquiries should take.

Dr. Ho on Postmastectomy Radiation Therapy

August 22nd 2013

Alice Y. Ho, MD, discusses postmastectomy radiation therapy for patients with breast cancer who have undergone breastreconstructive surgery.

Dr. Finn on New CDK 4/6 Inhibitors for Breast Cancer

August 19th 2013

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses new CDK 4/6 inhibitors for the treatment of breast cancer.

Subgroup Analysis: Certain Patients May Benefit More From Eribulin

August 19th 2013

A subgroup analysis from a phase III study showed that certain patients may benefit more from eribulin than capecitabine, and quality of life data suggest that patients may prefer eribulin because of a lower frequency of certain adverse events.

More Genetic Screening Needed for African-American Breast Cancer Patients

August 15th 2013

One in five African-American women with breast cancer carries an abnormality in at least one gene associated with breast cancer susceptibility.

Dr. Nielsen Discusses Using a Ki67 Assay in Breast Cancer

August 13th 2013

Torsten O. Nielsen, MD, PhD, FRCPC, professor, pathology, University of British Columbia, on using a Ki67 assay for patients with breast cancer.

CTC-Based Biomarkers Can Be Measured for Sensitivity to Novel Breast Cancer Drug

August 9th 2013

Biomarkers for sensitivity to etirinotecan pegol that are found in circulating tumor cells of breast cancer patients can be "reliably measured."